Heparin-like Polysaccharides Reduce Osteolytic Bone Destruction and Tumor Growth in a Mouse Model of Breast Cancer Bone Metastasis

TGF-β regulates several steps in cancer metastasis, including the establishment of bone metastatic lesions. TGF-β is released from bone during osteoclastic bone resorption and it stimulates breast cancer cells to produce osteolytic factors such as interleukin 11 (IL-11). We conducted a cell-based siRNA screen and identified heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) as a critical gene for TGF-β–induced IL-11 production in highly bone metastatic MDA-MB-231(SA) breast cancer cells. HS6ST2 attaches sulfate groups to glucosamine residues in heparan sulfate glycosaminoglycans. We subsequently showed how heparin and a high-molecular-weight Escherichia coli K5-derived heparin-like polysaccharide (K5-NSOS) inhibited TGF-β–induced IL-11 production in MDA-MB-231(SA) cells. In addition, K5-NSOS inhibited bone resorption activity of human osteoclasts in vitro. We evaluated the therapeutic potential of K5-NSOS and fragmin in a mouse model of breast cancer bone metastasis. MDA-MB-231(SA) cells were inoculated into the left cardiac ventricle of athymic nude mice which were treated with fragmin, K5-NSOS, or vehicle once a day for four weeks. Both heparin-like glycosaminoglycans inhibited weight reduction, decreased osteolytic lesion area, and reduced tumor burden in bone. In conclusion, our data imply novel mechanisms involved in TGF-β induction and support the critical role of heparan sulfate glycosaminoglycans in cancer metastasis as well as indicate that K5-NSOS is a potential antimetastatic and antiresorptive agent for cancer therapy. This study illustrates the potential to translate in vitro siRNA screening results toward in vivo therapeutic concepts. Mol Cancer Res; 10(5); 597–604. ©2012 AACR.

[1]  P. Seth,et al.  TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential , 2011, Cancer biology & therapy.

[2]  K. Mohammad,et al.  TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. , 2011, Cancer research.

[3]  Pekka Kohonen,et al.  Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis , 2010, Breast Cancer Research and Treatment.

[4]  Melec G Zeadin,et al.  Inhibition of osteolytic bone metastasis by unfractionated heparin , 2008, Clinical & Experimental Metastasis.

[5]  M. Butcher,et al.  The effects of heparin and low molecular weight heparins on bone. , 2008, Thrombosis research.

[6]  H. Väänänen,et al.  Improved methods for testing antiresorptive compounds in human osteoclast cultures , 2008, Journal of Bone and Mineral Metabolism.

[7]  L. Nissinen,et al.  O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. , 2007, Seminars in thrombosis and hemostasis.

[8]  G. Moneta.  Effect of Low Molecular Weight Heparin (Dalteparin) and Fondaparinux (Arixtra) on Human Osteoblasts In Vitro , 2006 .

[9]  Wei He,et al.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Binderup,et al.  Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. , 2005, Oncology reports.

[11]  B. Szende,et al.  Effect of Fraxiparine and heparin on experimental tumor metastasis in mice. , 2005, Anticancer research.

[12]  Marco Presta,et al.  Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. , 2005, Current pharmaceutical design.

[13]  D. Hawkins,et al.  Minimising the risk of heparin-induced osteoporosis during pregnancy , 2005, Expert opinion on drug safety.

[14]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Guise,et al.  Breast Cancer Metastasis to Bone: Mechanisms of Osteolysis and Implications for Therapy , 2005, Journal of Mammary Gland Biology and Neoplasia.

[16]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Lehenkari,et al.  The effects of bisphosphonates on the resorption cycle of isolated osteoclasts , 1994, Calcified Tissue International.

[18]  H. Nakato,et al.  Heparan sulfate fine structure and specificity of proteoglycan functions. , 2002, Biochimica et biophysica acta.

[19]  C. Rossi,et al.  Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. , 2002, Seminars in thrombosis and hemostasis.

[20]  H. Kock,et al.  Osteoblast Growth Inhibition by Unfractionated Heparin and by Low Molecular Weight Heparins: An in-vitro Investigation , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[21]  David R. Nadeau,et al.  Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Levine,et al.  Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread , 1999, Thrombosis and Haemostasis.

[23]  M. Bhandari,et al.  The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro , 1998, Thrombosis and Haemostasis.

[24]  C. Nelson-Piercy.  Heparin-induced osteoporosis. , 1998, Scandinavian journal of rheumatology. Supplement.

[25]  M. Lyon,et al.  The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific* , 1997, The Journal of Biological Chemistry.

[26]  F. Itoh,et al.  Low-molecular-weight heparin (dalteparin) demonstrated a weaker effect on rat bone metabolism compared with heparin. , 1997, Japanese journal of pharmacology.

[27]  B F Boyce,et al.  Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. , 1996, The Journal of clinical investigation.

[28]  J. Hirsh,et al.  Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. , 1996, Blood.

[29]  J. Douketis,et al.  The Effects of Long-term Heparin Therapy During Pregnancy on Bone Density , 1996, Thrombosis and Haemostasis.

[30]  J. Hirsh,et al.  The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. , 1995, Blood.

[31]  N. Razi,et al.  Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. , 1994 .

[32]  M. Lyon,et al.  Hepatocyte growth factor/scatter factor: a heparan sulphate-binding pleiotropic growth factor. , 1994, Biochemical Society transactions.

[33]  T. McCaffrey,et al.  Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. , 1994, Journal of cellular physiology.

[34]  D. Fernig,et al.  Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. , 1994, Progress in growth factor research.

[35]  F. Welt,et al.  Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2- macroglobulin inactive complex , 1989, The Journal of cell biology.

[36]  R. Baggs,et al.  A murine model of experimental metastasis to bone and bone marrow. , 1988, Cancer research.

[37]  J. Delaisse,et al.  Inhibition of bone resorption in culture by inhibitors of thiol proteinases. , 1980, The Biochemical journal.